Heparin-Natrium Leo

Heparin-Natrium Leo is a prescription anticoagulant that contains the active ingredient heparin sodium. It is supplied as an injectable solution for intravenous or subcutaneous administration, and is marketed within the European Union for use under medical supervision.

Heparin-Natrium Leo is indicated for several antithrombotic purposes in clinical practice.

- Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism. - Prophylaxis of clot formation in extracorporeal circuits such as dialysis or cardiopulmonary bypass. - Management of acute coronary syndromes, including unstable angina and myocardial infarction. - Peri‑operative thromboprophylaxis in patients undergoing major surgery. - Adjunct therapy in patients with atrial fibrillation at risk of embolic events.

Heparin-Natrium Leo may cause a range of adverse reactions, most of which are related to its anticoagulant activity.

Common: - Minor bleeding at injection sites or mucosal surfaces. - Mild thrombocytopenia without clinical sequelae. - Localized bruising or hematoma formation. - Transient elevation of liver enzymes.

Serious: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis. - Spinal or epidural hematoma following neuraxial procedures. - Severe allergic reactions such as anaphylaxis. - Adrenal gland hemorrhage.

When prescribing Heparin‑Natrium Leo, clinicians should observe several safety considerations.

- Monitor activated partial thromboplastin time (aPTT) or anti‑Xa levels to maintain therapeutic range. - Assess patient history for active bleeding, recent surgery, or trauma before initiation. - Use caution in individuals with renal or hepatic impairment, adjusting dose as needed. - Avoid use in patients with known heparin‑induced thrombocytopenia or a history of severe allergic reactions to heparin. - Consider potential risks during pregnancy; data are limited. - Evaluate concomitant use of other anticoagulants or antiplatelet agents for additive bleeding risk.

Heparin‑Natrium Leo can interact with several drug classes, influencing bleeding risk or anticoagulant effect.

Avoid: - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants) or thrombolytic agents. - Combination with antiplatelet drugs such as aspirin, clopidogrel, or ticagrelor without careful monitoring. - Simultaneous administration of high‑dose NSAIDs that impair platelet function.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) at low doses. - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents. - Corticosteroids, which may increase gastrointestinal bleeding risk. - Certain antibiotics (e.g., vancomycin, linezolid) that can affect coagulation parameters.